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Abstract: An increasing body of experience suggests that oligometas-
tasis represents a minimal metastatic state with the potential for cure or 
prolonged survival in selected patients treated with radical local therapy 
to all identified sites of disease. The main clinical scenarios managed 
by thoracic oncology specialists are pulmonary oligometastases from 
primary malignancies of other anatomic sites and primary lung cancer 
with oligometastases to lung or other organs. Surgery has been a main-
stay of treatment in these situations, with remarkably favorable out-
comes following pulmonary metastasectomy in well-selected patient 
cohorts. As with early stage lung cancer in patients who are medically 
inoperable, stereotactic ablative radiotherapy is emerging as a promi-
nent local treatment option for oligometastatic disease. We review the 
role and clinical experience of stereotactic ablative radiotherapy for 
pulmonary oligometastases and oligometastatic lung cancer.
(J Thorac Oncol. 2014;9: 1426–1433)
Metastatic disease in solid malignancies has historically been considered incurable, and the role of local thera-
pies including radiation therapy has primarily been pallia-
tive. Though metastases are generally widely disseminated, a 
minimal metastatic state, dubbed oligometastasis,1,2 has been 
recognized, with a distinct natural history and a prognosis 
intermediate between that of localized and widely metastatic 
disease.1–6 Oligometastasis may be loosely defined clinically as 
a limited number of metastatic lesions in a limited number of 
organs, generally identified by imaging, suggesting the poten-
tial benefit of radical local therapies. This definition has evolved 
with advances in diagnostic tools and systemic and local treat-
ments. Improved imaging, such as with whole body fluorode-
oxyglucose positron emission tomography (PET), has increased 
the likelihood of detecting limited metastasis. Furthermore, it is 
thought that the improved effectiveness of systemic therapy for 
occult microscopic disease, such as with individualized targeted 
therapy, may increase the chance of cure following ablation of 
limited imaging-detected metastases.
Aggressive local treatment, with the goal of ablating all 
known sites of disease, is an emerging treatment strategy for 
oligometastatic disease. However, determining the advantages 
or superiority of this approach compared to palliative systemic 
therapy or best supportive care is challenging because of the 
predominantly retrospective nature of existing data, which has 
raised substantial concerns for selection bias (performance 
status, disease-free interval, small metastatic burden) despite 
the use of techniques such as propensity score analyses. The 
ability to predict rapidly versus slowly progressive disease7 
would be of major importance for the design of customized 
therapeutic strategies and for prospective clinical trials.5,8
Perhaps the best evidence for a local ablative approach 
for oligometastatic disease comes from treatment, most com-
monly surgery, of lung or liver oligometastases from colorectal 
cancer, performed sequentially following systemic treatment.9 
This approach has since been extended to other cancer types. 
The two clinical scenarios most commonly treated by thoracic 
oncology specialists are pulmonary oligometastases from 
non-lung primary malignancies and primary lung cancer with 
or without oligometastases to the lung.
Stereotactic ablative radiotherapy (SABR), also known as 
stereotactic body radiotherapy, is a rapidly emerging technique 
for the treatment of oligometastatic disease. SABR’s role in the 
treatment of stage I lung cancer in patients is well established 
for inoperable patients,10 while for patients who can tolerate 
surgery, lobectomy is the standard of care. For a third category 
of patients, who are considered at high risk for complications 
from a lobectomy but who might tolerate sublobar resections 
or other invasive procedures such as SABR or radiofrequency 
ablation, there is a lack of consensus regarding appropriate 
treatment, and, as with the comparison between lobectomy and 
SABR, this issue has only been explored retrospectively.11 The 
attractiveness of SABR in oligometastatic disease is due to its 
feasibility in an ambulatory setting, low side-effect profile, 
and efficacy.12,13 SABR may be performed sequentially with 
systemic therapy and is delivered in a small number of frac-
tions (usually ≤5), varying in size from 5 to more than 20 Gy 
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each.14–18 Here, we review the use of SABR for the treatment 
of pulmonary oligometastases and oligometastatic lung cancer.
PULMONARY OLIGOMETASTASES
Lessons from the Surgical Experience
In 1997, the “International Registry on Lung Metastases,” 
a comprehensive research network among 18 major European 
and North American thoracic surgery departments, reported the 
results of 5206 lung metastasectomies, with 4572 (88%) com-
plete resections. The primary tumor was epithelial in 2260, sar-
coma in 2173, germ cell in 363, and melanoma in 328 patients.19 
The actuarial survival after complete resection was 36% at 5 
years, 26% at 10 years, and 22% at 15 years (median survival: 
35 months); the corresponding values for incomplete resection 
were 13% at 5 years and 7% at 10 years (median survival: 15 
months). Among complete resections, the 5-year survival was 
33% for patients with a disease-free interval (DFI: time between 
initial diagnosis and onset of lung metastatic disease) below 11 
months and 45% in patients with a DFI longer than 36 months; 
moreover, 5-year survival was superior for patients with single 
lesions (43% vs. 27%). These findings suggested a potentially 
curative role for surgery in a subset of metastatic patients, such 
as those with a completely resected single lesion (R0) and 
extended DFI. A recent large single-institution series confirmed 
these factors as prognostic,20 with a survival projection at 2 and 
5 years after complete resection (achievable in 85% of patients) 
of 74% and 46%, respectively. As a result of these findings, 
internationally accepted selection criteria for lung metastastec-
tomy are good performance status, absence of extra-pulmonary 
metastases, control of the primary tumor, possibility of com-
plete resection, and adequate respiratory function.21 All com-
prehensive series reported thus far comprise multiple primary 
tumors (e.g., epithelial, mesenchymal, germ cell tumors, and 
melanoma) and, among different epithelial tumors, histology 
has not been shown to be a significant prognostic factor. That 
being said, there are several reports from smaller series describ-
ing the results of surgical metastasectomy for colorectal can-
cer metastases. In a recent systematic review, Schlijper et al.22 
included 23 surgical reports, selected by a minimum follow-up 
of 24 months and a minimum of 50 patients, without regard to 
previous therapies, four of which were prospective studies. In 
this report, 2- and 5-year survival for metastasectomy ranged 
from 64% to 88% and 29% to 71.2%, respectively.22
Role for SABR
SABR is an ideal modality for treating pulmonary metas-
tases with the goal of achieving high rates of tumor control with 
minimal morbidity, noninvasively (Fig. 1). The use of SABR in 
treating metastatic pulmonary nodules was a natural extension 
of its established role in the treatment for early stage non–small-
cell lung cancers (NSCLC) not amenable to surgical resection. 
In oligometastatic disease, pulmonary lesions treated with 
SABR have a 1-year local control rate of 70% to 95%12,18,23–28; a 
more limited number of studies, reporting single-fraction sched-
ules, showed similar local control rates, especially for smaller 
tumors.29–31 All published series included a broad spectrum of 
different primary tumors, with the most represented histological 
subtypes being colorectal and lung cancer. Table 1 summarizes 
the results of clinical trials published over the last 10 years. The 
predominant clinical presentation was a single lung metastasis, 
with more limited reports of patients with two to five pulmo-
nary nodules. Siva et al.32 reviewed several studies on SABR for 
lung metastases, with a total of 488 patients treated with a wide 
range of technical approaches and different dose-fractionation 
schedules, and demonstrated a 2-year weighted overall survival 
of approximately 50%. Furthermore, in a prospective pilot study 
on oligometastatic patients (<5 lesions), survival at 3 years was 
around 30% and at 5 years did not exceed 25%.5
Few consistent prognostic factors have emerged from 
various studies to guide appropriate patient selection for 
the treatment of oligometastatic pulmonary tumors. In two 
sequential reports by Milano et al.3,5 that included oligomet-
astatic patients with less than five lesions in various organs 
including lung, the subgroup of breast cancer patients experi-
enced superior rates of survival,3 while among non-breast epi-
thelial subtypes, no significant differences were recorded. DFI 
(here defined as the interval between the initial diagnosis and 
the start of a local therapy for lung lesions) appears to have 
an impact for SABR, but results are unclear. Norihisa et al.18 
found that DFI longer than 3 years was associated with better 
overall survival, and Filippi et al.29 reported that patients with 
a DFI longer than 2 years had better cancer-specific survival, 
on both univariate and multivariate analyses. Conversely, 
other studies failed to show a survival difference according 
to DFI.23,24 Tumor volume appears to be prognostic, with bet-
ter outcomes in smaller tumors (<3.3 cc for gross tumor vol-
ume).23 Many patients included in these retrospective series, 
especially those with more than two pulmonary nodules, 
also received systemic therapy, either prior to or immediately 
after SABR, or at the time of a second progression. Few have 
been treated with further local therapies (including a second 
SABR) for oligometastatic recurrence or progression and it is 
difficult to estimate the contribution of these factors on sur-
vival. Reported 1- or 2-year progression-free survival (PFS) 
rates following SABR are highly variable, ranging from 25% 
to 70% and reflect the intrinsic heterogeneity of this patient 
FIGURE 1.  Stereotactic ablative radiotherapy (SABR) for oligo-
metastatic lung cancer. A 58-year-old woman treated with SABR 
for 2 lung metastases from colorectal caner (26 Gy in a single 
fraction each, prescribed to the 80% isodose line, over 2 days).
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population.23–26 A recent retrospective study, to the best of our 
knowledge the first designed to compare surgery with SABR 
for pulmonary oligometastases, suggested comparable rates of 
local control and PFS.33 In this single institutional experience 
of consecutive patients, SABR was offered as a second choice 
to patients not eligible for surgery. Most surgical patients 
(n = 68) had colorectal cancer (57%) or sarcoma (27%), while 
most SABR patients (n = 42) had colorectal (74%) or NSCLC 
(14%). With a median follow-up of 43 months, overall survival 
at 5 years was 41% for metastasectomy and 49% for SABR,. 
These results are promising, but the absence of prospective 
trials, large retrospective studies with adequate follow-up, 
meta-analyses, or collaborative network observational studies 
hampers our ability to evaluate the role of SABR in this set-
ting. Metastasectomy should still be regarded as the standard 
therapeutic option for pulmonary oligometastases, as SABR 
has not yet been evaluated in a large prospective study.
Radiobiological and Technical Aspects
The biological mechanisms of radiation-induced tumor 
cell death at fraction sizes greater than 8 to 10 Gy are likely 
more complex than previously thought. In addition to DNA 
damage, experimental models suggest that endothelial mem-
brane alterations occur after high radiation doses, inducing 
sphingomyelin-mediated endothelial apoptosis, which lead to 
microvasculature dysfunction.34 A combination of radiation-
induced endothelial damage and direct tumor cell killing may 
explain the “tumor ablative” effect of stereotactic radiotherapy. 
Data from the treatment of primary lung cancer suggest that 
biologically effective doses higher than 100 Gy (with tumors 
α/β = 10 Gy) are needed to achieve a tumor control probabil-
ity of more than 90%.35 This prescription criterion can be rea-
sonably extended to metastatic lung lesions. However, some 
uncertainties exist, mainly related to the variability in dose 
calculation algorithms and dose prescription conventions (in 
some studies, biologically effective dose values are calculated 
at the periphery, while in others, the isocenter). More recent 
data support the effectiveness of lower doses (prescribed to 
the planning target volume margin) in primary NSCLC, using 
a volume-adapted dose/fractionation schedules (with a mini-
mal dose of 80 Gy in 2 Gy equivalents).36
Technical considerations related to simulation, plan-
ning, and delivery, continue to evolve, including technical 
advances in patient immobilization (frameless devices), set-
up error correction (improved image guidance), respiratory 
motion management (respiratory gating, four-dimensional 
CT, tumor tracking), and treatment planning. Specific dose 
constraints for thoracic normal structures, adapted for differ-
ent fractionation schedules, are also widely available.37
Ongoing Trials
Current clinical trials evaluating the role for surgery 
or SABR for oligometastatic cancer include patients with a 
heterogeneous group of primary tumors. PulMiCC38 is a ran-
domized trial comparing surgery to active surveillance for pul-
monary oligometastases in colorectal cancer. The COMET39 
phase II trial randomizes patients to standard of care versus 
standard of care plus SABR for all known sites of metastatic 
and primary disease (bone, adrenal, lung, brain, and liver). 
The primary endpoint is overall survival, and secondary end-
points include quality of life, toxicity, PFS, local control, and 
number of cycles of further systemic therapy. The SAFRON40 
trial is a phase II randomized study comparing stereotactic 
radiotherapy and radiosurgery in oligometastatic pulmonary 
metastases. The primary endpoints are safety and toxicity. 
Finally, NCT0118563941 is a single-arm Phase II clinical trial, 
evaluating the role for SABR in NSCLC patients with a maxi-
mum of 5 metastatic sites, following primary chemotherapy. 
These innovative studies will better clarify the efficacy of local 
ablative strategies for the treatment of oligometastatic disease.
OLIGOMETASTATIC NSCLC AND SABR
Definition of Oligometastatic NSCLC
Definitive therapy for early stage NSCLC, through surgery 
or SABR, achieves 5-year survival rates in excess of 70%.42,43 
TABLE 1.  Clinical Trials of Stereotactic Ablative Radiotherapy for Pulmonary Oligometastatic Disease
Reference
No. of  
Patients
No. of  
Targets Radiation Dose
Median Follow- 
Up (Months) Outcomes
Fractionated/Single Fraction SABR
Onimaru et al.27 20 32 48 Gy/8 fx, 60 Gy/8 fx 18 48% 2-yr OS, 69.6% 3-yr LC for 48 Gy,  
100% 3-yr LC for 60 Gy
Yoon et al.26 53 80 30 Gy/3 fx, 40 Gy/4 fx, 48 Gy/4 fx 14 70% LC for 30 Gy, 77% for 40 Gy,  
100% LC for 48 Gy, 51% all 2-yr OS
Okunieff et al.28 50 125 50 Gy/10 fx, 48 Gy/6 fx, 57 Gy/3 fx 18.7 91% 3-yr LC, 50% 2-yr OS
Norihisa et al.18 34 43 48 Gy/4 fx, 60 Gy/5 fx, at isocenter 27 90% 2-yr LC, 84% 2-yr OS
Brown et al.25 35 69 5 Gy/1 fx to 60 Gy/4 fx 18 77% crude LC, 72.5% 2-yr OS
Rusthoven et al.12 38 63 60 Gy/3 fx at 80% 15.4 96% 2-yr LC, 39% 2-yr OS
Wulf et al.24 41 51 30 Gy/3 fx, 36 Gy/3 fx, 26 Gy/1 fx at 100% 13 80% 1-yr LC, 33% 2-yr OS
Ricardi et al.23 61 77 45 Gy/3 fx, 26 Gy/1 fx at 80% 20.4 89% 2-yr LC, 66.5% 2-yr OS
Single Fraction SABR Only
Hof et al.30 61 71 12 to 30 Gy at isocenter 14 65.1% 2-yr OS
Filippi et al.29 67 90 26 Gy at 80% 24 88.1% 2-yr LC, 70.5% 2-yr OS
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Conversely, disease that has spread to regional lymph nodes, treated 
with chemotherapy in combination with either surgery, radiother-
apy, or both, is difficult to eradicate and Stage IV disease treated 
exclusively with chemotherapy is considered incurable, with 
median survival rates of 13–14 months.44,45 Recently, oligometa-
static NSCLC (OLC), presenting with one to five synchronous or 
metachronous metastatic lesions, has emerged as a putatively dis-
tinct disease state.46 Locally ablative therapies are often used to 
treat OLC; however, the subset of patients within the spectrum of 
OLC who benefit from these interventions to metastatic sites or the 
primary lesion has not been conclusively identified. These issues 
are reflected by the heterogeneous survival outcomes reported in 
several retrospective and a limited number or prospective studies. 
One example of the latter, a single-arm phase II study, enrolled 39 
patients presenting with stage IV disease with four or less synchro-
nous sites of distant metastasis.47 The primary lesion was treated 
with radiotherapy alone or in combination with chemotherapy, and 
all sites of distant metastasis were treated with surgery or abla-
tive radiotherapy. Median survival was 13.5 months, though six 
patients were progression free after 2 years. Within the larger body 
of retrospective literature, median survival among OLC patients 
with controlled primary tumors in a recent systematic review 
was 19 months and aggressive treatment to the primary tumor 
improved OS, supporting the hypothesis that OLC represents a 
clinically distinct and potentially curable disease.48 Currently, the 
NCCN recommends surgical resection or SABR as an option for 
NSCLC presenting or progressing with solitary sites of metastasis 
to the brain or adrenals, though in the latter case only when the lung 
cancer is considered curable based on T and N staging.49
The Role for SABR
The role for SABR, as an alternative to surgery, in the 
definitive management of early stage lung cancers, has been 
well established. Although lobectomy remains the standard of 
care for patients who are surgical candidates, in patients who 
are medically inoperable, SABR provides primary tumor con-
trol rates that are comparable to lobectomy.10 SABR for primary 
early stage lung cancer is definitive and differs from radio-
therapy for advanced stage but potentially curable disease (T3, 
node positive), in that a smaller number of fractions (1–8) are 
used to deliver larger per fraction doses to the primary tumor 
only, without chemotherapy. Identical techniques can be used to 
ablate metastatic tumors within or outside of the lungs in OLC.
Brain Metastases
The majority of published studies of OLC have described 
the outcomes of patients with resected solitary brain metasta-
ses.48 Compared with stereotactic radiosurgery (SRS), con-
ventional surgery has the advantage of providing pathologic 
confirmation of metastatic disease and imparts superior rates of 
local control for larger tumors compared with SRS.50 However, 
adjuvant radiation to the resection cavity using SRS or whole 
brain radiotherapy (WBRT) is required following resection to 
ensure acceptable rates of local control.51,52 SRS has the advan-
tage of being able to treat unresectable tumors, easily treating 
multiple tumors in different regions of the central nervous sys-
tem (CNS) in a single course, of imparting acceptable rates 
of local control for small- to medium-sized tumors using a 
single modality, for being noninvasive, and, finally, is less toxic 
than whole brain irradiation (Fig. 2).53 The survival benefit of 
radiosurgery has been confirmed for a single brain metasta-
sis in a randomized Phase III clinical trial, and in that same 
study, improved functional autonomy was observed in patients 
with one to three brain metastases.54 In this regard, Flannery 
et al.55 described 42 patients with OLC treated for a solitary, 
synchronous brain metastasis. Patients had stage I–III thoracic 
disease and slightly more than half were treated definitively 
in the chest with chemoradiotherapy with or without surgery. 
Fourteen patients had node negative T1 or T2 disease; however, 
a subset analysis describing their outcomes was not reported. 
For 26 patients whose thoracic disease was treated definitively, 
median OS was approximately 26 months, twice that of patients 
whose thoracic disease was treated with chemotherapy alone. 
For their CNS tumors, all patients were treated definitively with 
SRS. In all but five cases, patients died due to progression of 
disease outside of the CNS, suggesting that an aggressive local 
approach to brain metastasis in patients who can tolerate defini-
tive treatment for their primary disease may be appropriate.
The question of whether adjuvant WBRT should be 
added to local ablative therapies to target subclinical lesions 
is unresolved. WBRT improves intracranial tumor control 
but carries an increased risk of neurotoxicity and may limit 
available salvage options. A recently completed EORTC study 
22952–26001 showed that, as with previous phase III random-
ized trials, adjuvant WBRT (after surgery or radiosurgery in 
patients with one to three brain metastases) reduces intracra-
nial events and neurologic death, but fails to improve the dura-
tion of functional independence or overall survival.56
Lung Metastases
As described in preceding sections, SABR is an effective 
means of treating pulmonary metastases.12 In the case of OLC, 
it is often not possible to determine whether one or both lung 
lesions represent primary lesions. If one or more lesions are 
presumed to be metastatic, according to the AJCC 2009, lesions 
in the ipsilateral or contralateral lung designate T4 or M1a 
classifications, respectively, in both cases indicating a better 
prognosis than extrapulmonary metastatic disease.57 Voltolini 
et al. described 43 patients treated for NSCLC with synchro-
nous multiple pulmonary tumors that were completely resected, 
60% of which were of identical histology, most often by wedge 
resection. As high as 86% of patients had a total of two lesions 
and 60% underwent staging PET scans. Median survival was 32 
months. On multivariate analysis, only node-positive disease or 
surgery prior to 2000, when PET was incorporated into routine 
staging, was associated with decreased survival.58 Assuming 
comparable rates of local control from SABR versus surgery,59 
and adequate regional lymph node staging from PET-CT,60 
treatment of patients with OLC restricted to lung metastasis 
with SABR appears to be a reasonable option.
Adrenal Metastases
Numerous small retrospective series have described out-
comes following resection of solitary adrenal metastases in OLC 
and a recent systematic review reported the results of those stud-
ies, separately describing the cohort of patients who were treated 
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for solitary adrenal metastases that presented synchronously with 
the primary lung tumor.61 Interestingly, a comparison of median 
survival favored metachronous over synchronous metastases (12 
months vs. 31 months); however, 5-year survival rates were com-
parable, at approximately 25%. A recent report described the use of 
SABR for treating 13 OLC patients with a solitary adrenal metas-
tasis using doses that ranged from 20 to 40 Gy delivered in five 
fractions. Median PFS was 12 months, median OS was 23 months, 
and the crude rate of local control was 77%.62
Tyrosine Kinase Inhibitors and 
Oligoprogressive Disease
Patients with metastatic lung cancer driven by epider-
mal growth factor receptor (EGFR) mutations or anaplastic 
lymphoma kinase gene rearrangements that are treated 
with the tyrosine kinase inhibitors (TKI), erlotinib, gefi-
tinib, afatinib,or crizotinib, have superior rates of survival 
compared to patients with cancers without these mutations 
treated with cytotoxic chemotherapies.63–66 Weickhardt et al.67 
reported a single institution retrospective study of 25 patients 
who developed oligoprogressive disease while being treated 
with either erlotinib or crizotinib monotherapy in the CNS 
alone or with four or fewer extracranial metastases. Patients 
were treated with SABR, SRS, WBRT, or surgery and main-
tained on that same drug. This strategy was associated with a 
median of six additional months before a second progression. 
In a similar study, 18 patients with EGFR-mutant, non-CNS, 
oligoprogressive disease received ablative treatment while 
FIGURE 2.  Stereotactic radiosurgery (SRS) for oligometastatic non–small-cell lung cancer (NSCLC). A 63-year-old man with 
initial stage III NSCLC treated 9 months previously with chemoradiation developed sudden onset seizures with left facial twitch-
ing and distortion, followed by jerking of the left arm and leg and loss of consciousness. Magnetic resonance imaging (MRI) 
revealed a single lesion in the left temperoparietal region measuring 16 × 12 × 13 mm. This lesion was subsequently targeted 
using a noncoplanar technique with 20 Gy delivered to the 80% isodose line in a single fraction.
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continuing TKI monotherapy. Median time to progression 
was 10 months and median OS following first local treatment 
was 41 months.68 Neither study contained subset analyses of 
patients treated with SABR. It should be noted that oligopro-
gressive and oligometastatic disease are similar but distinct 
entities; the former implies a limited number of new meta-
static lesions in a patient with disease that is otherwise con-
trolled. Furthermore, it is not considered standard of care for 
patients with NSCLC that has progressed on TKI therapy to 
continue that same drug, although variations to this approach 
will be tested in new or ongoing trials, in which SABR is not 
a component.69,70
Future Trials and Conclusions
Despite promising results from several retrospective 
studies and limited prospective data, randomized evidence that 
could eliminate the specter of selection bias or support stan-
dardized treatment strategies for oligometastatic cancer with 
SABR or other local ablative therapies is lacking (Table 2). 
A randomized Phase II trial, initiated at the University of 
Chicago,71 was recently closed due to slow accrual. At least 
one ongoing Phase II multiinstitutional trial is randomizing 
patients with OLC to chemotherapy followed by local ablative 
therapy to sites of metastasis (radiation or surgery) versus fur-
ther systemic therapy or surveillance.72 Another similar trial 
using radiation alone recently completed accrual.73 We await 
the results from these and other ongoing randomized control 
trials to assess the value of SABR in the treatment of pulmo-
nary oligometastases and OLC.
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